Showing results for: T cell therapy News
-
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:30 AM EST to discuss interim data from its dose escalation Phase ...
By Adicet Bio
-
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. ...
-
OncoImmunity will start collaborating with a US-based neoantigen specific T-cell therapy company
OncoImmunity announced today the signing of a collaboration agreement with a T cell therapy company based in the US . The companies will cooperate to access the predictive capabilities of OncoImmunity's artificial intelligence platform called the Immuneoprofiler™ to identify immunogenic neoantigens for the US partner’s T-cell platform. The collaboration agreement marks the increasing ...
-
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for ...
-
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day clinical data from the third dose cohort using 500 million DSG3-CAART cells in the DesCAARTes™ Phase 1 clinical trial ...
-
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of ...
-
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
MENLO PARK, Calif. and BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s investigational ...
By Adicet Bio
-
Carina Biotech inaugural symposium to be held on 18 May 2022 in Adelaide and virtually
Please Join Us on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech’s inaugural symposium Join us in Adelaide at the Hotel Grand Chancellor and virtually for Carina Biotech’s inaugural symposium showcasing our LGR5 CAR-T programand path to the clinic. Also hear from invited guests in the CAR-T cell therapy field who will share their latest research. RSVP to ...
-
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021
PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro studies supporting the early preclinical validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell ...
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
-
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some ...
-
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 ...
-
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American ...
-
Chimeric Licenses Viral Vector Technology from University of Pennsylvania for CDH17 Car T Program
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies. Under the amended agreement, Chimeric has acquired a non-exclusive know-how license to use ...
-
Aurora BioPharma to Attend 29th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, CA
Aurora BioPharma, a clinical stage biotechnology company, developing genetically programmed CAR T Cell Therapy to treat Liquid and Solid tumors, will attend the 29th Annual ROTH Conference on March 13, 2017 at the Ritz Carlton, Laguna Niguel, in Dana Point, CA. Robert Brooks, President and CEO, will be available for one-on-one meetings. About 29th Annual ROTH Conference The ROTH conference is ...
-
Aurora BioPharma Attends the 17th Annual Biotech in Europe Forum at the Congress Center Basel in Basel, Switzerland
Aurora BioPharma, Inc. announces its CEO, Robert Brooks, will attend the 17th Annual Biotech in Europe Forum for Global Partnering & Investment taking place September 26th - 27th, 2017 at the Congress Center Basel in Basel, Switzerland for partnering sessions. About Sachs 17th Annual Biotech in Europe Forum The event will be held for the fourth time in Basel to be close to the largest ...
-
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised ...
By IN8Bio Inc.
-
TVAX Biomedical Receives Fast Track Designation from the FDA
TVAX Biomedical today announced receipt of Fast Track Designation from the US Food and Drug Administration (FDA) for the use of its vaccineenhanced adoptive T cell therapy (VACT) for treatment of glioblastoma multiforme. “We are very pleased to receive Fast Track Designation by the FDA for glioblastoma multiforme (GBM),” stated Dr. Wayne Carter, Chief Executive Officer. Glioblastoma ...
-
Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen ...
By Tevogen Bio
-
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell therapy product candidate -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you